Denosumab Reduces the Incidence of New Vertebral Fractures in Men With Prostate Cancer

Prostate cancer is the most commonly diagnosed cancer among men worldwide. Androgen deprivation therapy has been a well established treatment for prostate cancer and improves disease-free survival in combination with radiation therapy in patients with locally advanced disease, but has been associated with bone loss and increased fracture risk. Fractures are an important contributor to morbidity associated with androgen deprivation therapy. Existing therapies have shown prevention of bone loss, but have yet to demonstrate reduction in fractures. Denosumab, a human monoclonal antibody that inhibits receptor activator for nuclear factor-κB ligand, impacts osteoclasts formation and survival, and has been shown to increase bone density in postmenopausal osteoporosis and other hormone deprivation states.